Clinical features associated with the invasive component in lentigo maligna of the head and neck: A retrospective study of 175 cases

E. Gérard(Université de Bordeaux), M. Beylot‐Barry, V. Pinsolle(Centre Hospitalier Universitaire de Bordeaux), P Guillot(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), O. Cogrel(Centre Hospitalier Universitaire de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), C. Goehrs(Bordeaux Population Health), A Ricard(Centre Hospitalier Universitaire de Bordeaux), B. Vergier(Centre Hospitalier Universitaire de Bordeaux)
Annales de Dermatologie et de Vénéréologie
June 21, 2022
10.1016/j.annder.2022.03.008
Cited by 5

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k